MedTrace Logo

Suicide Prevention Intervention for Schizophrenia-Spectrum Disorders

NCT04221269 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2023-07-11

No results posted yet for this study

Summary

The current project is a pilot randomized controlled trial to test the Coping Long-term with Active Suicide Program for schizophrenia-spectrum disorders (CLASP-S) for patients following a psychiatric hospitalization. Participants will be assigned to enhanced treatment as usual (ETAU) alone vs CLASP-S plus ETAU. Participants complete assessments at baseline during their psychiatric hospitalization and at 3 months (mid-treatment) and 6 months (post-treatment) following discharge. The primary aim is to assess the feasibility and acceptability of CLASP-S. The secondary aim is to estimate the effects of CLASP-S on reducing suicidal thoughts and behaviors relative to ETAU.

Conditions

Interventions

BEHAVIORAL

Enhanced Treatment as Usual

Routine community care plus assessment feedback reports to clinicians.

BEHAVIORAL

Coping Long-term with Active Suicide Program for Schizophrenia

Adjunctive psychosocial intervention for suicide prevention involving in person, family, and phone sessions.

Sponsors & Collaborators

  • American Foundation for Suicide Prevention

    collaborator OTHER

  • Butler Hospital

    lead OTHER

Principal Investigators

  • Brandon Gaudiano, PhD · Butler Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-12-01
Primary Completion
2023-06-01
Completion
2023-06-01

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04221269 on ClinicalTrials.gov